FDA Approves KISQALI FEMARA CO-PACK — Novartis Pharmaceuticals Corporation

Novartis has secured FDA approval for the co-packaged fixed-dose combination of KISQALI and Femara (ribociclib and letrozole), a strategic move aimed at improving medication adherence for breast cancer patients. This approval strengthens Novartis's stronghold in the advanced breast cancer market by simplifying treatment regimens for patients managing both hormonal and CDK4/6 inhibition therapies.